You are here

  • Home
  • Archive
  • Volume 32, Issue 7
  • Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD)

Article metrics

Article menu
Download PDFPDF
Clinical trial
Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD)

 

Online download statistics by month:

Online download statistics by month: July 2021 to March 2023

AbstractFullPdf
Jun 2021705652
Jul 202143178
Aug 20211852
Sep 2021171313
Oct 202120565
Nov 202124767
Dec 202112543
Jan 202220778
Feb 20225031313
Mar 202217656
Apr 202218655
May 202215775
Jun 202217099
Jul 20225652410
Aug 20222791212
Sep 202226355
Oct 2022281103
Nov 202233498
Dec 202211453
Jan 202322023
Feb 202313567
Mar 202311352
Total4428231189